Patents Assigned to ONCOPEP, INC.
  • Peptide vaccines and pembrolizumab for treating breast cancer
    Patent number: 12059463
    Abstract: The disclosure features, inter alia, combination therapies comprising pembrolizumab and one or more immunogenic XBP1-, CD138-, and CS1-derived peptides. The therapies herein can be used, e.g., for inducing an immune response in a subject having a cancer, and treating a cancer such as breast cancer, e.g., triple negative breast cancer.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: August 13, 2024
    Assignee: ONCOPEP, INC.
    Inventors: Doris Peterkin, Marc A. Cohen